Genprex Inc Dossier - Source-backed chat

Genprex Inc

GNPXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)-0.29

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.56Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $2.1M

Enterprise Value −$13.1M

Shares Outstanding 819.7K diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Genprex, Inc. is a clinical-stage gene therapy company advancing systemic, non-viral plasmid therapies for lung cancer (Reqorsa®) and preclinical gene therapies for diabetes (GPX-002). While the company has successfully extended its cash runway into the second half of 2027 through aggressive at-the-market (ATM) equity financing, it remains a high-risk, pre-revenue biotech. The investment case is balanced between promising clinical milestones expected in the second half of 2026 (interim analyses for Acclaim-1 and Acclaim-3) and severe dilution risks, coupled with an active Nasdaq delisting warning for failing to maintain the $1.00 minimum bid price.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Interim clinical data for Reqorsa® fails to show sufficient efficacy, or safety concerns emerge, halting the Acclaim trials. The reverse stock split fails to sustain the stock price above $1.00, leading to Nasdaq delisting. Continued high cash burn forces heavy dilution at depressed valuations, accelerating the going concern risk and exhausting the cash runway earlier than projected.

Base CaseCentral scenario

The company successfully completes enrollment and delivers positive interim clinical data for both the Acclaim-1 (NSCLC) and Acclaim-3 (SCLC) trials in the second half of 2026. The board utilizes its newly approved authority to execute a reverse stock split, resolving the Nasdaq minimum bid price deficiency. Preclinical progress on GPX-002 continues toward IND filing, while cash burn is managed within the current $18.05 million reserve, supplemented by controlled ATM usage.

Bull CaseUpside scenario

Genprex's bull case is anchored on its dual-platform approach: the oncology program (Reqorsa) targeting large unmet needs in NSCLC and SCLC with FDA Fast Track and Orphan Drug designations, and the diabetes program (GPX-002) which has shown preclinical success in reversing hyperglycemia. Positive clinical biomarker data (correlating Trop-2 and PTEN levels with prolonged PFS) and a cash runway extending into the second half of 2027 provide a solid foundation for clinical advancement.

Scenarios reflect our research view at the research date.

Key Investment Merits

Differentiated non-viral systemic delivery system (ONCOPREX®) utilizing lipid nanoparticles to deliver tumor suppressor genes.
FDA Fast Track Designations for both NSCLC and SCLC programs, plus Orphan Drug Designation for SCLC.
Strong academic and clinical partnerships, including a sponsored research agreement with MD Anderson Cancer Center to study predictive biomarkers (TROP2 and PTEN).
Expanded pipeline potential with GPX-002 showing positive preclinical proof-of-concept in reversing hyperglycemia in Type 2 diabetes models.

Key Investment Risks

Substantial doubt about the company's ability to continue as a going concern due to recurring losses and zero revenue.
Severe shareholder dilution, with outstanding shares increasing significantly to fund operations via ATM programs.
Nasdaq delisting risk following the June 10, 2026 non-compliance letter regarding the $1.00 minimum bid price rule.
High clinical development risk inherent to early-stage gene therapies.

Thesis Invalidation Triggers

Negative or inconclusive interim analysis results from the Acclaim-1 or Acclaim-3 trials in the second half of 2026.
Inability to regain compliance with Nasdaq listing requirements, resulting in a transition to over-the-counter (OTC) trading.
Failure to secure FDA clearance for IND-enabling studies of GPX-002.
Cash burn accelerating significantly beyond the projected runway, forcing emergency dilutive financing.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.